Recommendations guide the use of time-to-event end points in clinical trials for prostate cancer, suggesting the evolution of endpoints based on emerging data.
PCWG2 recommends increasing emphasis on time-to-event end points (ie, failure to progress) as decision aids in proceeding from phase II to phase III trials. Recommendations will evolve as data are generated on the utility of intermediate end points to predict clinical benefit.
No takes yet. Share an insight, caveat, or question.
Scher et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: